AU7002501A - Vitronectin receptor antagonist pharmaceuticals for use in combination therapy - Google Patents
Vitronectin receptor antagonist pharmaceuticals for use in combination therapyInfo
- Publication number
- AU7002501A AU7002501A AU7002501A AU7002501A AU7002501A AU 7002501 A AU7002501 A AU 7002501A AU 7002501 A AU7002501 A AU 7002501A AU 7002501 A AU7002501 A AU 7002501A AU 7002501 A AU7002501 A AU 7002501A
- Authority
- AU
- Australia
- Prior art keywords
- receptor antagonist
- combination therapy
- vitronectin receptor
- antagonist pharmaceuticals
- pharmaceuticals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100022337 Integrin alpha-V Human genes 0.000 title 1
- 108010048673 Vitronectin Receptors Proteins 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
- C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
- C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21321200P | 2000-06-21 | 2000-06-21 | |
| PCT/US2001/019794 WO2001098294A2 (en) | 2000-06-21 | 2001-06-21 | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU7002501A true AU7002501A (en) | 2002-01-02 |
Family
ID=22794180
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU7002501A Pending AU7002501A (en) | 2000-06-21 | 2001-06-21 | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| AU2001270025A Ceased AU2001270025B2 (en) | 2000-06-21 | 2001-06-21 | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001270025A Ceased AU2001270025B2 (en) | 2000-06-21 | 2001-06-21 | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1296678A2 (en) |
| AU (2) | AU7002501A (en) |
| CA (1) | CA2413957A1 (en) |
| WO (1) | WO2001098294A2 (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6511649B1 (en) | 1998-12-18 | 2003-01-28 | Thomas D. Harris | Vitronectin receptor antagonist pharmaceuticals |
| JP2002532440A (en) | 1998-12-18 | 2002-10-02 | デュポン ファーマシューティカルズ カンパニー | Vitronectin receptor antagonist drug |
| US6569402B1 (en) | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| CA2410887C (en) | 2000-06-02 | 2012-07-24 | Bracco Research Usa | Compounds for targeting endothelial cells, compositions containing the same and methods for their use |
| US8263739B2 (en) | 2000-06-02 | 2012-09-11 | Bracco Suisse Sa | Compounds for targeting endothelial cells, compositions containing the same and methods for their use |
| EP1311292A2 (en) * | 2000-06-21 | 2003-05-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| IL152941A0 (en) * | 2000-06-21 | 2003-06-24 | Bristol Myers Squibb Co | Fused heterocyclic compounds and kits and pharmaceutical compositions containing the same |
| WO2003011226A2 (en) * | 2001-08-01 | 2003-02-13 | Smithkline Beecham Corporation | Products and drug delivery vehicles |
| US7319149B2 (en) * | 2003-06-13 | 2008-01-15 | Bristol-Myers Squibb Pharma Company | Chelants and macrocyclic metal complex radiopharmaceuticals thereof |
| AU2005221283C1 (en) | 2004-03-17 | 2011-02-03 | Lars Michael Larsen | Prevention of retinopathy by inhibition of the visual cycle |
| JP2007529474A (en) * | 2004-03-19 | 2007-10-25 | シュペーデル・エクスペリメンタ・アーゲー | 5-Amino-4-hydroxy-7- (1H-indolemethyl) -8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension |
| CN100369606C (en) * | 2004-04-15 | 2008-02-20 | 中国人民解放军军事医学科学院毒物药物研究所 | Inclusion containing raltitrexed and preparation |
| CN100471496C (en) * | 2004-04-15 | 2009-03-25 | 中国人民解放军军事医学科学院毒物药物研究所 | Inclusion containing raltitrexed and its powder injection |
| US8986650B2 (en) | 2005-10-07 | 2015-03-24 | Guerbet | Complex folate-NOTA-Ga68 |
| JP5368099B2 (en) | 2005-10-07 | 2013-12-18 | ゲルベ | A compound comprising a moiety for recognition of a biological target coupled to a signal moiety capable of complexing with gallium |
| TW200732305A (en) * | 2005-12-23 | 2007-09-01 | Yung Shin Pharmaceutical Ind | Cancer chemotherapy |
| WO2009006404A2 (en) | 2007-06-29 | 2009-01-08 | Sunesis Pharmaceuticals, Inc. | Heterocyclic compounds useful as raf kinase inhibitors |
| CL2008001933A1 (en) | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Pyrimidine derived compounds, raph kinase inhibitors; intermediate compounds; preparation procedure; pharmaceutical composition; and its use to treat proliferative, cardiac, neurodegenerative, inflammatory, bone, immunological, viral disease, among others. |
| FR2942227B1 (en) | 2009-02-13 | 2011-04-15 | Guerbet Sa | USE OF BUFFERS FOR RADIONUCLEID COMPLEXATION |
| PT2528602T (en) | 2010-01-28 | 2017-01-12 | Eagle Pharmaceuticals Inc | Formulations of bendamustine |
| FR2968999B1 (en) | 2010-12-20 | 2013-01-04 | Guerbet Sa | CHELATE NANOEMULSION FOR MRI |
| FR2980364B1 (en) | 2011-09-26 | 2018-08-31 | Guerbet | NANOEMULSIONS AND THEIR USE AS CONTRAST AGENTS |
| FR3001154B1 (en) | 2013-01-23 | 2015-06-26 | Guerbet Sa | MAGNETO-EMULSION VECTORIZED |
| EP3929196B1 (en) * | 2013-09-24 | 2023-08-23 | FUJIFILM Corporation | Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof |
| PT3275883T (en) * | 2015-03-25 | 2021-07-07 | Fujifilm Corp | Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same |
| WO2020007822A1 (en) | 2018-07-02 | 2020-01-09 | Conservatoire National Des Arts Et Metiers (Cnam) | Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof |
| CN113368235B (en) * | 2021-05-11 | 2022-11-15 | 上海师范大学 | Gd-NGQDs/BTS @ PLGA-PEG nano material and preparation method and application thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0095906B1 (en) * | 1982-05-27 | 1986-10-22 | National Research Development Corporation | Improvements relating to compounds useful in radiotherapy or chemotherapy |
| CA2240439A1 (en) * | 1995-12-22 | 1997-07-03 | The Dupont Merck Pharmaceutical Company | Novel integrin receptor antagonists |
| CA2210600A1 (en) * | 1996-07-17 | 1998-01-17 | Takashi Houkan | Inhibitor of tumor metastasis or recurrence |
| GB9708265D0 (en) * | 1997-04-24 | 1997-06-18 | Nycomed Imaging As | Contrast agents |
| IL121440A0 (en) * | 1997-07-31 | 1998-01-04 | Yeda Res & Dev | The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives |
| WO1999040947A2 (en) * | 1998-02-11 | 1999-08-19 | Resolution Pharmaceuticals Inc. | Angiogenesis targeting molecules |
| JP4487019B2 (en) * | 1998-03-31 | 2010-06-23 | ランサス メディカル イメージング インコーポレイテッド | Drugs for imaging angiogenic diseases |
| DE19845798A1 (en) * | 1998-09-29 | 2000-04-13 | Schering Ag | Use of neoangiogenesis markers for diagnosis and therapy of tumors, agents containing them, and methods for their production |
| EP1140203B1 (en) * | 1998-12-18 | 2007-05-23 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
-
2001
- 2001-06-21 AU AU7002501A patent/AU7002501A/en active Pending
- 2001-06-21 CA CA002413957A patent/CA2413957A1/en not_active Abandoned
- 2001-06-21 EP EP01948554A patent/EP1296678A2/en not_active Withdrawn
- 2001-06-21 WO PCT/US2001/019794 patent/WO2001098294A2/en not_active Ceased
- 2001-06-21 AU AU2001270025A patent/AU2001270025B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001098294A3 (en) | 2003-01-09 |
| WO2001098294A2 (en) | 2001-12-27 |
| CA2413957A1 (en) | 2001-12-27 |
| AU2001270025B2 (en) | 2005-08-18 |
| EP1296678A2 (en) | 2003-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU7002501A (en) | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy | |
| IL142958A0 (en) | Vitronectin receptor antagonist pharmaceuticals | |
| EP1000031A4 (en) | Vitronectin receptor antagonist | |
| IL152700A0 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists | |
| HUP0302382A3 (en) | Il-8 receptor antagonists and pharmaceutical compositions containing them | |
| AU2001271435A1 (en) | Vitronectin receptor antagonist pharmaceuticals | |
| IL149495A0 (en) | Pharmaceutical formulations comprising p2t receptor antagonist and anti-thrombotic agent and use thereof in therapy | |
| EP1017387A4 (en) | Vitronectin receptor antagonist | |
| HUP0300599A3 (en) | Il-8 receptor antagonists, pharmaceutical compositions containing them and their use | |
| IL138245A0 (en) | Vitronectin receptor antagonists | |
| AU9259801A (en) | Alpha v integrin receptor antagonists | |
| HUP0302003A3 (en) | Il-8 receptor antagonists and pharmaceutical compositions containing them | |
| AU2003267088A8 (en) | Chemokine receptor antagonists as therapeutic agents | |
| EG24025A (en) | Vitronectin receptor antagonist | |
| HUP0102931A3 (en) | New n-(triazolylmethyl)-piperazine derivatives with neurokinin receptor antagonist activity | |
| HUP0201300A3 (en) | Il-8 receptor antagonist imidazoidinylidene-2-imino derivatives and pharmaceutical compositions containing them | |
| HUP0302614A3 (en) | Il-8 receptor antagonists and pharmaceutical compositions containing them | |
| GC0000203A (en) | Vitronectin receptor antagonists | |
| HUP0300470A3 (en) | Il-8 receptor antagonists, pharmaceutical compositions containing them and their use | |
| EP1102587A4 (en) | Vitronectin receptor antagonists | |
| EP1208101A4 (en) | Vitronectin receptor antagonists useful for the treatment of strokes | |
| AU9088401A (en) | Alpha v integrin receptor antagonists | |
| HUP0300181A3 (en) | Vitronectin receptor antagonist bicyclic compounds, their preparation and pharmaceutical compositions containing same | |
| GB0022922D0 (en) | Compounds for use in medicine | |
| HUP0300305A3 (en) | Il-8 receptor antagonists, pharmaceutical compositions containing them and their use |